Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy aims to shrink breast tumors before surgery

NCT ID NCT06650748

ENROLLING_BY_INVITATION Disease control Sponsor: Peking University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether adding the targeted drug dalpiciclib to standard hormone therapy (letrozole) before surgery can improve outcomes for women with HR+/HER2- early-stage breast cancer. The study enrolls 100 women aged 18-70 whose tumors have a high genetic risk score and show a poor early response to hormone therapy. The goal is to see if this combination leads to a complete or near-complete disappearance of the tumor by the time of surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Dalpiciclib (a CDK4/6 inhibitor) and letrozole (an aromatase inhibitor)
What this could lead to
If successful, this could lead to a more personalized treatment approach for early-stage breast cancer, potentially improving response rates before surgery.
What could go wrong
This is a small, early-phase trial (100 participants) at a single center, so results may not apply broadly. Side effects from the drug combination, such as low blood cell counts or fatigue, are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER EARLY-STAGE BREAST CANCER

Contacts and locations

Locations

  • Beijing Cancer Hospital

    Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.